Showing 15 posts of 142 posts found.


Almirall picks up Allergan’s dermatology portfolio to for $650m

August 3, 2018
Medical Communications, Sales and Marketing Allergan, Almirall, dermatology, pharma

Allergan has sealed a deal to sell its dermatology portfolio, comprising five brands, to Spanish pharmaceutical firm Almirall for $650 …

Allergan sues Pfizer over opioid crisis lawsuits

August 3, 2018
Medical Communications Allergan, Litigation, Pfizer, lawsuits, opioid crisis, opioids

Allergan are suing American pharma giant Pfizer over potential damages that they may be forced to pay relating to hundreds …


US court overturns Allergan’s controversial attempts to avoid Restasis patent review

July 23, 2018
Sales and Marketing Allergan, Mylan, Restasis, US, dry eye, pharma

The US Court of Appeals for the Federal Circuit has seen fit to authorise a US Patent and Trademark Office …


Allergan appoints ex-Abbott exec in “Board refreshment” move

June 15, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Allergan, appointment, pharma

Allergan has announced another move in its “refreshment” of its executive Board of Directors with the appointment of Thomas C …


Allergan’s atogepant fulfils primary endpoint in episodic migraine

June 12, 2018
Manufacturing and Production, Research and Development Allergan, atogepant, migraine, pharma

Allergan has made ground in its quest to become “the headache company” with the release of new Phase 2b/3 data …


Allergan mauled by investors in public letter

June 6, 2018
Medical Communications, Research and Development Allergan

Last week, Allergan announced that a strategic review of its operations had led to a decision to divest its women’s …


Axovant snatches Teva and Allergan execs to strengthen management

June 5, 2018
Manufacturing and Production, Medical Communications Allergan, Axovant, Teva, appointment, pharma

Axovant has announced reinforcements to its management team with two new additions, snatching up Allergan’s current Chief Medical Officer Dr …


Allergan aims to appease investors with non-core units sell off

May 31, 2018
Medical Communications Allergan, biotech, drugs, pharma, pharmaceutical

Allergan’s share price has been on a steady downward trajectory for the last year and investors are becoming increasingly frustrated …


Allergan recalls 170,000 birth control packs in US over pregnancy fears

May 30, 2018
Research and Development Allergan, FDA, Taytulla, US, birth control, pharma

Allergan has issued a voluntary recall of its birth control medication in the US marketplace after an error in packaging …


Amgen/Novartis potential blockbuster migraine med gets FDA nod

May 18, 2018
Medical Communications, Sales and Marketing Allergan, Amgen, Novartis, biotech, drugs, migraine, pharma, pharmaceutical

The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig …


Allergan unveils second bout of Phase 3 success in migraine

April 30, 2018
Research and Development, Sales and Marketing Allergan, migraine, pharma, ubrogepant

Allergan has revealed new data from the second of two Phase 3 studies into the efficacy of its calcitonin gene-related …

Allergan out but Takeda sticks to guns on Shire

April 20, 2018
Medical Communications, Sales and Marketing Allergan, Shire, Takeda, biotech, drugs, pharma, pharmaceutical

Allergan performed an odd about-turn after initially declaring its interest in pursuing a deal for Shire, before reneging on that …

Rumours Allergan is looking to offload $5bn women’s health unit

April 3, 2018
Manufacturing and Production, Sales and Marketing Allergan, Restasis, biotech, drugs, pharma, pharmaceutical

According to a piece by Bloomberg, Allergan is looking at options to divest its women’s health unit in a move …

Latest content